Physician profile
Robert N Bilkovski
NPI 1750455366
$367,744.03
in general payments reported to CMS, 2019-2025
3 companies · $11K in 2025
The $11K reported for 2025 was more than what 98% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $125K · 2021: $135K · 2022: $47K · 2023: $13K · 2024: $4,375 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,500.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $151,025.28 | 2019-2025 | |
| Gyrus Acmi, L.P. | $133,420.81 | 2020-2021 | |
| Olympus Medical Systems Corporation | $83,297.94 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bilkovski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.